Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A, Martinotti G, Sensi SL, Schifano F. Chiappini S, et al. Among authors: sensi sl. Pharmaceuticals (Basel). 2023 Jul 11;16(7):994. doi: 10.3390/ph16070994. Pharmaceuticals (Basel). 2023. PMID: 37513906 Free PMC article.
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Martinotti G, Dell'Osso B, Di Lorenzo G, Maina G, Bertolino A, Clerici M, Barlati S, Rosso G, Di Nicola M, Marcatili M, d'Andrea G, Cavallotto C, Chiappini S, De Filippis S, Nicolò G, De Fazio P, Andriola I, Zanardi R, Nucifora D, Di Mauro S, Bassetti R, Pettorruso M, McIntyre RS, Sensi SL, di Giannantonio M, Vita A; REAL-ESK Study Group. Martinotti G, et al. Among authors: sensi sl. Bipolar Disord. 2023 May;25(3):233-244. doi: 10.1111/bdi.13296. Epub 2023 Jan 18. Bipolar Disord. 2023. PMID: 36636839 Free article.
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Chiappini S, d'Andrea G, De Filippis S, Di Nicola M, Andriola I, Bassetti R, Barlati S, Pettorruso M, Sensi S, Clerici M, Dell'Osso B, Vita A, Martinotti G. Chiappini S, et al. Eur Neuropsychopharmacol. 2023 Sep;74:15-21. doi: 10.1016/j.euroneuro.2023.04.011. Epub 2023 May 4. Eur Neuropsychopharmacol. 2023. PMID: 37148637 Free article.
Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
d'Andrea G, Chiappini S, McIntyre RS, Stefanelli G, Carullo R, Andriola I, Zanardi R, Martiadis V, Sensi SL, Sani G, Clerici M, Di Lorenzo G, Vita A, Pettorruso M, Martinotti G. d'Andrea G, et al. Among authors: sensi sl. Am J Geriatr Psychiatry. 2023 Dec;31(12):1032-1041. doi: 10.1016/j.jagp.2023.06.016. Epub 2023 Jul 8. Am J Geriatr Psychiatry. 2023. PMID: 37479669 Free article.
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).
Pettorruso M, Guidotti R, d'Andrea G, De Risio L, D'Andrea A, Chiappini S, Carullo R, Barlati S, Zanardi R, Rosso G, De Filippis S, Di Nicola M, Andriola I, Marcatili M, Nicolò G, Martiadis V, Bassetti R, Nucifora D, De Fazio P, Rosenblat JD, Clerici M, Maria Dell'Osso B, Vita A, Marzetti L, Sensi SL, Di Lorenzo G, McIntyre RS, Martinotti G; REAL-ESK Study Group. Pettorruso M, et al. Among authors: sensi sl. Psychiatry Res. 2023 Sep;327:115378. doi: 10.1016/j.psychres.2023.115378. Epub 2023 Jul 28. Psychiatry Res. 2023. PMID: 37574600 Free article.
Corrigendum to "Comparing fast-acting interventions for treatment-resistant depression: An explorative study of accelerated HF-rTMS versus intranasal esketamine" [Brain Stimul 16 (2023)].
Pettorruso M, d'Andrea G, Di Carlo F, De Risio L, Zoratto F, Miuli A, Benatti B, Vismara M, Pompili E, Nicolò G, Niolu C, Siracusano A, Sensi SL, Dell'Osso B, Di Lorenzo G, Martinotti G; ReModula Study Group. Pettorruso M, et al. Among authors: sensi sl. Brain Stimul. 2023 Sep-Oct;16(5):1361. doi: 10.1016/j.brs.2023.09.003. Epub 2023 Sep 14. Brain Stimul. 2023. PMID: 37716051 Free article. No abstract available.
LSD-induced changes in the functional connectivity of distinct thalamic nuclei.
Delli Pizzi S, Chiacchiaretta P, Sestieri C, Ferretti A, Tullo MG, Della Penna S, Martinotti G, Onofrj M, Roseman L, Timmermann C, Nutt DJ, Carhart-Harris RL, Sensi SL. Delli Pizzi S, et al. Among authors: sensi sl. Neuroimage. 2023 Dec 1;283:120414. doi: 10.1016/j.neuroimage.2023.120414. Epub 2023 Oct 18. Neuroimage. 2023. PMID: 37858906 Free article. Clinical Trial.
The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
d'Andrea G, Pettorruso M, Di Lorenzo G, Rhee TG, Chiappini S, Carullo R, Barlati S, Zanardi R, Rosso G, Di Nicola M, Andriola I, Marcatili M, Clerici M, Dell'Osso BM, Sensi SL, Mansur RB, Rosenblat JD, Martinotti G, McIntyre RS. d'Andrea G, et al. Among authors: sensi sl. J Affect Disord. 2024 Mar 1;348:314-322. doi: 10.1016/j.jad.2023.12.038. Epub 2023 Dec 23. J Affect Disord. 2024. PMID: 38145840
192 results